A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.